The purpose of the Protein Chemistry and Proteomics Shared Resource is to provide essential services in peptide synthesis, protein separation, electrophoresis, protein identification, mass spectrometry, differential proteomics, biomarker discovery, small molecule analysis and peptide quantification, computing informatics and in silico molecular modeling to Cancer Center members. This is accomplished by providing state-of-theart services, expertise and technologies. Services include: (1) Solid phase peptide synthesis by Fmoc orthogonal chemistry;(2) Synthesis of peptide/protein specific immunogens;(3) Protein separation by reverse phase HPLC and FPLC methods;(4) one-dimensional (1-D) and 2-dimensional (2-D) PAGE of protein mixtures including DIGE separation and analysis;(5) Edman chemical sequencing;(6) Protein identification by nanoLC-MS/MS methods;(7) Differential Proteomics / Biomarker discovery by tandem MS and targeted MS (e.g., MRM) methods;(8) Small molecule analysis by LC-MS and MRM methods;(9) Protein PTM analysis by nanoLC-FT-ICR mass spectrometry, and (10) Computational services for peptide design, de novo modeling of proteins, protein identification, and differential proteomics using iTRAQ and label-free methods. Future plans of the shared resource will include the development of Electron Transfer Dissociation (ETD) mass spectrometry for efficient mapping of protein post-translational modifications and chemical peptide ligation synthesis utilizing thioester methods for the chemical synthesis of small proteins and polypeptides. Cancer Center member use of the Shared Resource has increased by nearly 38% over this grant period, to more than 97 members in 2007. Cancer Center use represents 65% of the total services provided by the Shared Resource. The Protein Chemistry and Proteomics Shared Resource has been vital to Cancer Center members supporting a broad array of peer review funded research that has produced more than 400 publications during the current funding period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-39
Application #
8465660
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
39
Fiscal Year
2013
Total Cost
$253,924
Indirect Cost
$78,134
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8

Showing the most recent 10 out of 1129 publications